
Immunic IMUX
$ 0.83
16.87%
Quarterly report 2025-Q3
added 11-13-2025
Immunic Interest Expense 2011-2026 | IMUX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Immunic
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.05 M | 2.54 M | -1.96 M | -1.35 M | 4.9 M | 1.99 M | 456 K | -73 K | 13 K | 39 K | 56 K | -15 K | 413 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.9 M | -1.96 M | 458 K |
Quarterly Interest Expense Immunic
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5 K | 22 K | 1.17 M | - | 582 K | 436 K | -2.09 M | - | 35 K | 54 K | 1.18 M | - | -1.34 M | -1.4 M | 620 K | - | -915 K | 1.22 M | -2.18 M | - | 612 K | 760 K | 503 K | - | 904 K | 259 K | 349 K | - | 8 K | - | -66 K | - | -29 K | -27 K | -12 K | - | -18 K | 3 K | 7 K | - | 22 K | -40 K | 49 K | - | 7 K | -5 K | -2 K | - | -5 K | -4 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.22 M | -2.18 M | 18.1 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-807 K | - | -15.15 % | $ 60.3 M | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Amarin Corporation plc
AMRN
|
8 K | $ 15.08 | 2.24 % | $ 6.15 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Adagene
ADAG
|
1.11 M | $ 2.95 | 10.3 % | $ 166 M | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.51 | -1.68 % | $ 8.45 B | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-20.7 M | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Ascendis Pharma A/S
ASND
|
65.5 M | $ 222.25 | 0.1 % | $ 5 B | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
4.16 M | - | -6.81 % | $ 3.04 B | ||
|
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | ||
|
Athira Pharma
ATHA
|
3.96 M | - | - | $ 269 M | ||
|
Athersys
ATHX
|
103 K | - | 3.77 % | $ 22.4 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 4.4 | 2.8 % | $ 9.57 B | ||
|
Autolus Therapeutics plc
AUTL
|
9.29 M | $ 1.44 | -1.37 % | $ 367 M | ||
|
Amneal Pharmaceuticals
AMRX
|
11.8 M | $ 14.79 | 1.83 % | $ 4.57 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
Codexis
CDXS
|
-10.4 M | $ 1.26 | -1.94 % | $ 92.5 M | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.33 | 1.75 % | $ 14.6 M |